Bridging the Divide from Laboratory Discovery to Patient Care
Watch our Video!
What is CDCM?
The Center for Definitive and Curative Medicine (CDCM) is the translational arm of the Institute for Stem Cell Biology and Regenerative Medicine. The CDCM was established as a joint initiative of the Stanford University School of Medicine, Stanford Health Care and Stanford Children’s Health. Currently, Dr. Matthew Porteus serves as the Director with Dr. Tony Oro as the Co-Director. Dr. Maria Grazia-Roncarolo serves as the Founding Director.
The CDCM provides the know-how, organizational and physical infrastructure to support investigator-initiated clinical translational studies on cell and gene therapy (CGT) from initial discovery through completion of clinical proof-of-concept trials. Stanford Medicine’s clinical enterprise provides an exemplary clinical environment in which to deploy cures. The CDCM supports the development of life-changing and curative treatments for patients who come to Stanford to receive the highest level of care.
Why Stanford University?
A number of distinguishing features make Stanford particularly well-positioned to succeed
Pre-eminent, highly-funded cell and gene therapy program
Significant investment in translational infrastructure on campus
State-of-the-art GMP facility
Excellence in clinical care and access to patient populations
NORD Rare Disease Center of Excellence
The National Organization for Rare Diseases (NORD) is a nonprofit that strives to connect patients with rare diseases to world class care that can help with diagnoses, specialists, or clinical trials. In addition to serving as an extensive database for rare diseases, NORD advances research in the field through research grants, studies, patient registries, and partnerships. Classified as a NORD Center of Excellence, Stanford Medicine Children's Health is part of the extensive network that aims to provide patients with rare diseases with world class diagnoses and treatments.